CPhi Japan to See Increased Participation of International Generic API Firms

The 2018 edition of CPhI Japan expo is set to witness increased participation of international generic API companies and suppliers even though the market is regarded as an innovative drug focussed one. This is because, as revealed in the CPhI Japan 2018 report, after years of gradual reforms, the Japanese pharma economy is becoming extremely welcoming for generics and overseas manufacturers – particularly those that can combine exemplary regulatory records with competitive pricing. By joining the Pharmaceutical Convention Inspection (PIC/S) scheme in 2014, Japan has opened its doors to new entrants.

The pharma exhibition will take place at the Big Sight Exhibition Centre, Tokyo, Japan from 18-20 April, 2018. CPhI Japan features companies working across ingredients, contract services, biopharmaceuticals, machinery, technology, and packaging. The event will also feature a finished dosage formulation zone (FDF) for 2018, building on the increasing diversity of the API supplier base.

Over 21,000 visitors from 56 countries and 550 exhibitors from 30 countries are expected to participate in the event highlighting the country’s growing internationalisation.

The CPhI Japan conference will feature insights from the Ministry of Health, Labour and Welfare (MHLW), the Pharmaceuticals and Medical Devices Agency, the Japanese Society of Generic and Biosimilar Medicines, and the Japan Pharmaceutical Traders’ Association. Another major development in Japan, especially for new market entrants, is the implications of the 2018 ‘Pricing system reform and introduction of cost-effectiveness assessment’ on which the conference will host a keynote address. Conversely, for buyers in the region, information and access to the international partners will be integral to establishing a robust supply chain, with the event also hosting an ‘International API Procurement Forum’ – specifically designed to empower the Government’s requirement for 80% generic market penetration by 2020. 

pharmaceutical chemicals“CPhI Japan is an accurate bellwether of the wider market trends in the country, and this year we are seeing an acceleration of interest in generics and biologicals, particularly biosimilars – which the market has been previously resilient towards. But there is also more generally increased international interest and investment in all product classes –including innovative medicine – thanks to deregulation and streamlined new drug approval processes,” commented Ms. Laura Murina, Brand Manager, CPhI Japan at UBM.